What's Going On With Gene Therapy Company Bluebird Bio Stock Today?
The agreement, which also includes a team of biotech executives, will see Bluebird Bio’s stockholders receive $3.00 per share in cash, along with a contingent value right, which could potentially bring the total payout to up to $9.84 per share, depending on the product portfolio performance.
Cash-strapped gene-therapy company Bluebird bio agreed to be acquired by private-equity firms Carlyle Group and SK Capital ...
Bluebird Bio announced Friday it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK ...
Bluebird Bio announced it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK ...
The pioneering gene therapy developer will be acquired by investment firms Carlyle Group and SK Capital for a fraction of ...
There is a catch. If the private equity firms can boost sales of bluebird’s three gene therapies to $600 million—over any ...
The future of the CDC’s vaccine advisory committee seems uncertain: A scheduled February meeting for the ACIP, which advises ...
BofA moved to No Rating on Bluebird Bio (BLUE) after the company announced it has entered a definitive merger agreement under which Carlyle and ...
Hand crews will work over the next year to form a new fuel modification zone in the Bluebird Canyon area of Laguna Beach, the ...
Penny and Fritz Brandau, members of the Black River Audubon Society and the Ohio Bluebird Society, will give a presentation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback